个人简介

Dr. Ami Shah is an assistant professor of medicine at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include rheumatology and scleroderma. Dr. Shah serves as the director of clinical and translational research for the Johns Hopkins Scleroderma Center. She is a graduate of the Massachusetts Institute of Technology and Johns Hopkins. She completed her internal medicine residency training at Stanford University Hospital & Clinics. She returned to Johns Hopkins for her rheumatology post-doctoral fellowship. During her fellowship training, she earned her Master of Health Science in clinical investigation at the Johns Hopkins Bloomberg School of Public Health. Dr. Shah’s clinical practice is focused on the broad spectrum of patients with scleroderma and related disorders, and her expertise includes management of complications such as Raynaud’s phenomenon, digital ischemia, pulmonary hypertension, cardiac dysfunction, myopathy, aggressive skin disease and concomitant cancer. Dr. Shah teaches post-doctoral fellows in her clinic about the evaluation and management of scleroderma. Dr. Shah was recognized by the American College of Rheumatology Research and Education Foundation and the Arthritis Foundation with a Career Development Bridge Funding Award in 2011. She is a member of the American College of Physicians and the American College of Rheumatology.

研究领域

Scleroderma and Raynaud’s phenomenon; Connection between cancer and scleroderma; Methods to detect cardiopulmonary complications in scleroderma

Dr. Shah has an active research program studying various aspects of scleroderma and Raynaud’s phenomenon. She is investigating the connection between cancer and scleroderma, as her early data suggest cancer may drive the development of scleroderma in some patients. She also conducts epidemiological studies and participates in clinical trials to examine 1) methods to detect cardiopulmonary complications in scleroderma, 2) biological and imaging markers of Raynaud’s severity and 3) drugs that may improve various aspects of the disease (such as skin, lung or vascular complications).

近期论文

查看导师最新文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L. Close Temporal Relationship Between Onset of Cancer and Scleroderma in Patients with RNA Polymerase I/III Antibodies. Arthritis Rheum. 2010 Sep; 62(9): 2787-95. PMID: 20506513 Shah AA, Rosen A. Cancer and Systemic Sclerosis: Novel Insights into Pathogenesis and Clinical Implications. Curr Opin Rheumatol. 2011 Nov; 23(6): 530-5. PMID: 21825998. Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, Boin F, Fava A, Thoburn C, Kinde I, Jiao Y, Papadopoulos N, Kinzler KW, Vogelstein B, Rosen A. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014 Jan 10;343(6167):152-7. PMID: 24310608. Moinzadeh P, Fonseca C, Hellmich M, Shah AA, Chighizola C, Denton CP, Ong VH. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Research & Therapy. 2014 Feb 14;16(1):R53 [Epub ahead of print]. PMID: 24524733. Shah AA, Casciola-Rosen L, Rosen A. Cancer-induced Autoimmunity in the Rheumatic Diseases. Arthritis Rheumatol. 2015 Feb;67(2):317-26. PMID: 25371098. Shah AA, Hummers LK, Casciola-Rosen L, Visvanathan K, Rosen A, Wigley FM. Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheumatol. 2015 Apr;67(4):1053-61. PMID: 25605296. Shah AA, Casciola-Rosen L. Cancer and Scleroderma: A Paraneoplastic Disease with Implications for Malignancy Screening. Curr Opin Rheumatol. 2015, in press.